BIOGEN for BIOGEN
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
Health Issues HCR
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARON BILL | — |
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
| TYLER HANSON | — |
| MATTHEW ITZKOWITZ | — |
| ALI LAKHANI | — |
Pharmacy PHA
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARON BILL | — |
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
Taxation/Internal Revenue Code TAX
Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
Trade (domestic/foreign) TRD
Trade-related public policy around tariffs and intellectual property, no related bills
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.